Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.

Personalization of care through the identification of the most appropriate therapy for each patient can optimize clinical and economic outcomes. Future real-world evidence research could help establish the value of prophylactic options in targeted populations such as the non-inhibitor male PwHA.